What Do Device Investors Want?

Perhaps the question most often posed by entrepreneurs and start-up company executives is, "What are device investors looking for these days?" At Windhover's recent IN3 West conference, industry leaders provided several different perspectives on that question. In this article, we excerpt portions of a discussion that featured two prominent organizations with long-term commitments to medical device investing, but which operate from different points on the investor spectrum: Medtronic Inc. and the Carlyle Group.

Perhaps the question most often posed by entrepreneurs and start-up company executives is, "What are device investors looking for these days?" At Windhover’s IN3 West conference, held in Las Vegas, NV, in February of this year, we attempted to provide several different perspectives on that question through panel presentations. In this article, we are excerpting portions of a discussion that featured two prominent organizations with long-term commitments to medical device investing, but which operate from different points on the investor spectrum: Medtronic PLC and the Carlyle Group.

Beginning in the late 1990s, Medtronic went through one of the most transformative dealmaking cycles in industry history with its acquisitions of Sofamor Danek, MiniMed, AVE, and Xomed, among others....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Medtronic To Spin Out Diabetes Unit As New Products Solidify Turn-Around Story

 
• By 

Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By 

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By 

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

China Still ‘Attractive’ For Danaher Despite $50M VBP Drag

 
• By 

Apart from the reimbursement-driven turbulence in diagnostics, other aspects of Danaher’s China business are showing signs of resilience. Patient volumes remain strong and the company does not see evidence that the Chinese government is attempting to actively push Western suppliers out of its healthcare system.

More from Business

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By 

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.